Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India's Medical Tourism Growth Threatens Drug-Resistance Spread

This article was originally published in PharmAsia News

Executive Summary

India as a growing mecca for medical tourism may be creating a breeding ground for drug-resistant bacteria as physicians supply patients with antibiotics

India as a growing mecca for medical tourism may be creating a breeding ground for drug-resistant bacteria as physicians supply patients with antibiotics.

Japan's first case of a drug-resistant bacterium was reported in a man who had received health treatment in India. Health authorities are concerned about the spread of bacteria resistant to antibiotics because of over-use of the drug, particularly for patients who get treatment in countries such as India, where medical tourism is growing at the rate of 27 percent a year. (Click here for more)

"India May Be Hotbed Of Drug-Resistant Bacteria" - Asahi Shimbun (Japan) (10/5/10)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel